Providing a blood toxicity evaluation method for a drug to be evaluated and a model for evaluating blood toxicity of a drug to be evaluated, which is excellent in clinical predictability of bone marrow toxicity. A human GM-CSF / IL-3 gene is introduced into a NOG mouse, and the evaluation target drug is administered to a humanized modified NOG mouse in which the leukocyte content in human blood is 20% by number or more And measuring the number of human-derived blood cells for the sample of the modified NOG mouse after administering the evaluation target drug, and comparing the control with the solvent administered in place of the evaluation target drug And a step of evaluating that the evaluation target drug has hematological toxicity when the number of human-derived blood cells changes.
展开▼
